

Supplementary Table 1. Total anti-RBD immunoglobulins, Anti-RBD IgG, Anti-S1 IgA, Surrogate virus neutralization test against Wild-type, B.1.1.7, B.1.351 and B.1.617.2 in the vaccinees in this study.

Results	CoronaVac/CoronaVac (n = 170)	AZD1222/AZD1222 (n = 169)	CoronaVac (full vac.) + AZD1222 (n = 210)
Immunoglobulin anti-RBD (U/mL) GMT (95% CI)	97.94 (82.59, 116.1)	877.1 (763.5, 1008)	7947 (7277, 8679)
IgG anti-RBD (BAU/mL) GMT (95% CI)	128.0 (113.7, 144.1)	178.0 (155.5, 203.8)	1492 (1367, 1629)
IgA anti-S1 (OD/CO) Median [IQR] (min-max)	0.88 [0.55, 1.79] (0.15-8.11)	1.00 [0.53, 1.73] (0.26-7.30)	5.25 [3.94, 9.00] (0.70-9.00)
sVNT (Wild-type, Euroimmun) (% Inhibition) [Median (IQR)]	51.56 [33.43, 72.98] (1.36-95.17)	76.52 [53.10, 87.97] (-0.27-98.76)	99.49 [99.18, 99.62] (94.03-99.79)
sVNT (Wild-type,	66.60	88.86	97.76

GenScript) (%)	[48.86, 79.41]	[75.65, 96.35]	[96.98, 97.83]
Inhibition) [Median (IQR)]	(21.12-92.50)	(52.94-98.12)	(86.56-97.99)
sVNT (B.1.1.7,	42.11	75.94	97.24
GenScript) (%)	[28.97, 58.31]	[61.48, 88.38]	[94.71, 97.65]
Inhibition) [Median (IQR)]	(7.21-73.15)	(38.23-97.80)	(82.67-98.07)
sVNT (B.1.351,	34.86	65.20	92.88
GenScript) (%)	[20.46, 47.33]	[43.13, 77.99]	[86.82, 94.82]
Inhibition) [Median (IQR)]	(4.15-72.43)	(13.33-90.92)	(67.14-96.56)
sVNT (B.1.617.2,	48.93	83.93	97.22
GenScript) (%)	[36.12, 63.42]	[67.66, 94.59]	[95.55, 97.90]
Inhibition) [Median (IQR)]	(12.46-85.45)	(51.62-97.83)	(78.33-98.09)
